Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

844
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
844
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Factors Involved in Tuberculosis Recurrence in a Low-incidence Setting; Reactivation Predominates Over Reinfection in a 30-year Surveillance Study.

Open forum infectious diseases·2026
Same author

Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Recommendations for Performing Spirometry.

Archivos de bronconeumologia·2026
Same author

Exploiting the Biorefinery Potential of Spent Mushroom Substrate: The Time to Do It Is Now.

Molecules (Basel, Switzerland)·2025
Same author

A novel use of temporary ICL during DMEK to prevent gas-induced opacification of a scleral-fixated Carlevale IOL.

American journal of ophthalmology case reports·2025

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K

Recent developments in tuberculosis vaccines.

Dessislava Marinova1, Jesus Gonzalo-Asensio, Nacho Aguilo

  • 1Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, C/ Domingo Miral s/n, 50009 Zaragoza, Spain.

Expert Review of Vaccines
|November 8, 2013
PubMed
Summary

Developing new tuberculosis vaccines faces challenges in animal models and understanding immune responses. Identifying correlates of protection is crucial for advancing clinical trials of these vital tuberculosis vaccines.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.9K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

9.8K

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.9K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

9.8K

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a significant global health burden, necessitating novel vaccine strategies.
  • Decade-long efforts have focused on developing new vaccines against tuberculosis.
  • Existing vaccines, like Bacille Calmette-Guérin (BCG), have limitations, driving the need for improved prophylactic and therapeutic options.

Purpose of the Study:

  • To review recent advancements in the global portfolio of tuberculosis vaccines.
  • To discuss vaccines for prophylactic use and as boosts to BCG.
  • To examine therapeutic vaccines aimed at enhancing chemotherapy.

Main Methods:

  • Literature review of recent developments in tuberculosis vaccine research.
  • Analysis of vaccine strategies, including prophylactic and therapeutic approaches.
  • Evaluation of challenges in current vaccine development and testing.

Main Results:

  • Progress is being made in tuberculosis vaccine development, with diverse candidates in the pipeline.
  • Limitations exist in animal model screening and understanding of required immunological responses.
  • Lack of knowledge regarding long-lived immunity hinders vaccine efficacy assessment.

Conclusions:

  • Optimizing advanced clinical trials in endemic regions is essential.
  • Identifying correlates of protection is critical for successful tuberculosis vaccine development.
  • Further research into immunological responses and long-lived immunity is needed.